Biogen Q4 Adjusted EPS $2.95 Misses $3.18 Estimate, Sales $2.39B Miss $2.46B Estimate
Portfolio Pulse from Benzinga Newsdesk
Biogen (NASDAQ:BIIB) reported Q4 earnings of $2.95 per share, missing the consensus estimate of $3.18, marking a 27.16% decrease from last year. Quarterly sales were $2.39B, also below the $2.46B estimate, representing a 6.21% year-over-year decline.
February 13, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's Q4 earnings and sales missed analyst estimates, with a significant decrease compared to last year's figures.
Missing both earnings and sales estimates, especially with a notable decrease from the previous year's figures, is likely to negatively impact investor sentiment and potentially lead to a short-term decrease in Biogen's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100